The extracellular matrix gene, *Svep1*, orchestrates airway patterning and the transition from lung branching morphogenesis to alveolar maturation in the mouse

Foxworth N^{1*}, Wells J^{2*}, Ocaña-Lopez S¹, Muller S^{1,3,4}, Denegre J², Palmer K², McGee T², Memishian W², Murray SA², Donahoe PK^{1,3}, Bult CJ^{2,+}, and Loscertales M^{1,3,+}

¹Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston, MA 02114 □ □

²The Jackson Laboratory, Bar Harbor, ME 04609

³Harvard Medical School, Boston, MA 02114

⁴Broad Institute of MIT, Cambridge, MA 02142

*Equal Contributions

+Co-senior authors

Correspondence: Maria Loscertales, mloscertales@mgh.harvard.edu; Carol J. Bult, carol.bult@jax.org

Author Contributions: ML designed and led the execution, data analysis, and interpretation for lung phenotyping, imaging, RNA Seq, and lung explant experiments with contributions from NF and SOL. SM contributed to the analysis of the RNA Seq data. *Svep1* mutants were generated by the Knockout Mouse Project center at The Jackson Laboratory under the direction of SAM. JD and KP performed microCT on *Svep1* mutants and maintained the initial colonies of *Svep1*^{-/-} animals with oversight from SAM. JW, WM, TG performed animal husbandry for timed matings to generate embryos for lung phenotyping and performed the scRNA Seq experiment. TM, WM and CJB analyzed the scRNA Seq data. ML and CJB wrote the manuscript in consultation with PKD, JW, SM, TM, and WM.

Competing Interest Statement: The authors have declared no competing interest.

Data availability: Transcriptomics data from this study will be submitted to a public data archive upon acceptance in a peer-reviewed journal.

Keywords: *Svep1*, lung development, lung branching, alveolar differentiation

Abstract

Proper lung development and function requires two independent but interrelated processes: branching morphogenesis to form the airway tree, and alveolar cell differentiation for peripheral gas exchange. The disruption of either branching or differentiation results in severe respiratory deficiencies and often in neonatal death. The molecular mechanisms that control branching patterns and the transition to alveolar differentiation are not completely understood. Here we report on the *in vitro* and *in vivo* characterization of the lungs of mouse embryos lacking a functional *Svep1* gene. Our data demonstrate that the SVEP1 extracellular matrix protein is critical for airway patterning and for the process of transitioning from branching to alveolar maturation. *Svep1*^{-/-} embryos on a C57BL/6J genetic background are characterized by hypoplastic lungs and a disorganized increase in distal airway tips which disrupts airway architecture and lobe shape. The lungs of *Svep1* knockout embryos also have defects in alveolar differentiation. *In vitro* lung explant experiments demonstrated that SVEP1 normally inhibits branching morphogenesis and that treatment with a SVEP1 peptide can rescue the branching defects observed in *Svep1* knockouts. Our findings reveal for the first time that *Svep1* is essential for constructing the basic airway architecture and for the transition from lung branching to alveolar differentiation. Our results suggest therapeutic strategies to enhance lung development in patients with life-threatening respiratory disorders such as the lung hypoplasia and prematurity observed in neonates with congenital diaphragmatic hernia (CDH).

Introduction

The mammalian lung consists of conductive airways (bronchi and bronchioles) and terminal alveoli which function in peripheral gas exchange. Two developmental processes underlie the lung's basic architecture: branching morphogenesis to build the airway tree structure, and differentiation to generate specialized cells. Cellular differentiation to form specialized cells in different regions of the lung occurs predominantly after the formation of the tracheobronchial tree ¹. For alveolar cell differentiation to occur, the molecular genetic signaling that promotes branching must cease as lung branching antagonizes differentiation ².

In the laboratory mouse, branching morphogenesis starts soon after the formation of the lung buds from the ventral foregut endoderm at embryonic day 9.5 (E9.5). During the pseudoglandular stage (E12.5 – E16.5), epithelial progenitors at the bud tips undergo an iterative process of budding and bifurcations into the surrounding mesenchyme. During the canalicular (E16.5-17.5) stage the respiratory tree is expanded in diameter and length. The vasculature develops along the airway and terminal airway tips widen to form saccules. During the saccular stage (E17.5-P5) the alveolar epithelium differentiates into alveoli-cuboidal cells (type II pneumocytes) responsible for surfactant protein C (SPC) production and the thin gas-exchanging cells (type I pneumocytes). Primitive septa arise at this stage. Secondary septation and alveolar maturation occur during postnatal development ³.

The airway tree geometry of the lung is generated by three local branching modes: domain, planar, and orthogonal ⁴. During domain branching, new branches grow perpendicularly around

the circumference of the parent branch and generate the initial scaffold of each lobe which, in turn, determines the overall shape of the lung. Planar bifurcation occurs at the tips of the airway epithelium and generates branches in the same plane resulting in the thin edges of the lung lobes. Orthogonal bifurcation generates branches perpendicular to prior branches thus filling in the interior. Trifurcations are rare and appear principally at the lung surface^{5; 6}. As branching proceeds, proximal-distal patterning is established, and cellular specification follows⁷⁻⁹. Thus, bud tip progenitors persist and proliferate, then undergo differentiation into type I and type II pneumocytes⁸, and the cells of the primal airway stalk differentiate into multiple proximal cell types¹⁰⁻¹³.

Mesenchymal-epithelial interactions are essential for branching morphogenesis and several signaling pathways, including the FGF pathway, play central roles in lung morphogenesis¹⁴. Fibroblast growth factor 10 (FGF10) secreted by mesenchymal cells acts through the FGFR2 receptor to maintain a permissive environment for branching morphogenesis. FGF10 maintains distal epithelial progenitor cells (SOX9⁺ cells) in an undifferentiated state¹⁵⁻²⁶. FGF10 signaling plays a pivotal role in alveolar and mesenchymal differentiation as FGF10⁺ cells give rise to bronchial airway smooth muscle cells during early branching²⁷⁻³⁰. The extra cellular matrix (ECM) also plays important roles in lung morphogenesis, including epithelial branching and alveolarization³¹⁻³⁶. The ECM also contributes to organ shape³⁷.

SVEP1 (Sushi, Von Willebrand Factor Type A, EGF, and Pentratix Domains-Containing 1; HGNC:15985), also called Polydom, is an extracellular matrix (ECM) protein which is ubiquitously expressed in adult mice and plays roles in cell adhesion³⁸, epidermal differentiation³⁹, and lymphatic vessel formation and remodeling^{40; 41}. According to the Mouse Genome Informatics (MGI) database⁴², *Svep1*(MGI:1928849) homozygous mutant mice display “complete preweaning lethality, edema, abnormal skin coloration, thick epidermis, acanthosis, tail/limb abnormalities, and defects in lymphatic vascular development and valve formation”^{39; 41; 43; 44}.

We investigated the role of *Svep1* in branching morphogenesis and alveolar cellular differentiation by *in vivo* and *in vitro* characterization of the lungs of mice homozygous for the *Svep1*^{tm1b(EUCOMM)Hmg} allele (MGI:6115217; hereafter, *Svep1*^{-/-}) generated by the Knockout Mouse Phenotyping Program (KOMP2) program at The Jackson Laboratory⁴⁴. We determined that the loss of *Svep1* disrupts the basic lung branching program resulting in an irregular lung lobe shape due to an aberrant increase in distal airway tips. Alveolar and smooth muscle differentiation is also disrupted in the lungs of *Svep1*^{-/-} embryos. We demonstrated that SVEP1 acts as a negative regulator of branching and that branching abnormalities, but not airway smooth muscle differentiation, are independent of FGF signaling. As the loss of *Svep1* disrupts alveolar differentiation, SVEP1 peptides or inhibition of SVEP1 downstream targets such as SOX9 and members of the FGF signaling pathway are potential candidates for therapeutic interventions for conditions in which lung prematurity is a major contributor to mortality.

Methods

Svep1 mutant mice. *Svep1* mutant mice (B6N(Cg)-*Svep1*^{tm1b(EUCOMM)Hmgu}/J) were generated as part of the Knockout Mouse Phenotyping Program (KOMP2) by inserting the L1L2_Bact_P cassette upstream of exon 8 of *Svep1*. This cassette contains a flippase recombinase target (FRT) site followed by a lacZ sequence and a loxP site. The first loxP site is followed by a neomycin resistance gene, a second FRT site, and a second loxP site. A third loxP site is inserted downstream of exon 8. The construct was introduced into embryonic cells and embryonic stem cell clone HEPD0747_6_B06 was injected into B6(Cg)-*Tyr*^{c-2J}/J blastocysts. Resulting chimeric males were bred to C57BL/6NJ female mice to generate heterozygous tm1a (i.e., knockout first) animals⁴⁵. No homozygous mice were recovered at weaning from heterozygous intercrosses. Heterozygous tm1a mice were then bred to B6N.Cg-Tg (Sox2-cre)1Amc/J mice to remove the floxed neomycin sequence and exon 8 of *Svep1*. Resulting offspring were bred to C57BL/6NJ mice to remove the *cre*-expressing transgene.

Mice and embryos were genotyped by PCR using the primers shown below. The wild type (WT) PCR product is 389 base pairs (bp) in length and the mutant (MUT) product is 540 bp. DNA was isolated from tissues obtained by either ear notching or tail tipping using the Hot Shot method⁴⁶. Each PCR reaction consisted of 1µg of DNA, 1 µg of each genotyping primer, 4 µl of 5M betaine, 4 µl of 5X Phusion buffer, 2 µl of dNTP mix (10 mM each dNTP;) and 0.2 µl of Phusion DNA polymerase. Reactions were amplified by 25 cycles of PCR with an annealing temperature of 60° C and visualized by electrophoresis on a 2% agarose gel.

<u>primer name</u>	<u>primer sequence</u>
<i>Svep1</i> WT F	5'-AGCTTTTCCACTCTAGCAAGC-3'
<i>Svep1</i> WT R	5'-CATGCAGGTCCTTTTCATCCT-3'
<i>Svep1</i> MUT F	5'-CGGTCGCTACCATTACCAGT-3'
<i>Svep1</i> MUT R	5'-TCCATCCTTCAGATTTGGTCA-3'

Histology. Mouse embryos were euthanized by decapitation at E14.5 E16.5, or E18.5. Tails were collected for genotyping and whole lungs were extracted and fixed in 4% paraformaldehyde (PFA) and embedded in paraffin. Paraffin tissue blocks were sectioned (5 µm) and stained for Hematoxylin and Eosin (H&E) following standard procedures. Images were acquired using a Nikon80i microscope

For Toluidine Blue Staining, mouse embryos were euthanized by decapitation at E18.5. Tails were collected for genotyping and lungs were fixed in a combination of 2% paraformaldehyde (PFA)/2% glutaraldehyde in 0.1M cacodylate buffer for 24 hr at 4° C. Lungs were post-fixed in 2% aqueous osmium tetroxide for 2 hr at room temperature, rinsed in 1X phosphate buffered saline (PBS), then dehydrated with a series of ethanol, from 40% through 100%. For each ethanol stage, lungs were incubated for 15 minutes at room temperature. The final 100% ethanol stage was repeated three times. Dehydrated embryos were infiltrated with Embed 812 resin (Electron Microscopy Sciences, Hatfield, PA) and embedded in the same resin. The blocks with embedded embryos were cured at 60° C for 24 hr. One-micron thick

sections were cut using a diamond knife and baked onto glass slides. Slides were covered in 0.5% aqueous toluidine blue for 30 seconds, rinsed in running water, and then allowed to air dry before a coverslip was placed on the slide.

In situ hybridization (ISH). For whole mount *in situ* hybridization of *Svep1*, a 725bp segment of the *Svep1* transcript (NM_153366.4; 746-11179) was PCR amplified (PCR Master Mix, Promega) with one pair of exon-exon boundary overlapping primers (5' TGTGGTCCTCCAAGTCACGTA 3'; 5' CCAGCAGACAGCAGAGTATGT 3') designed using NCBI's Primer-BLAST⁴⁷. The purified PCR fragment was cloned into the pCR™II-TOPO® TA vector (TOPO® TA Cloning® Kit, Dual Promoter, ThermoFisher), and transformed into One Shot® TOP10 Chemically Competent Cells, ThermoFisher). Transformed colonies on agar plates were selected by ampicillin resistance following 24 hr at 37° C. The orientation of the insert after linearization of the vector with *SpeI* restriction digestion (New England Biolabs, Inc.) was determined by Sanger sequencing. Sense and anti-sense Digoxigenin-11-UTP labeled probes (DIG RNA Labeling Mix, Sigma-Aldrich) were synthesized with SP6 and T7 RNA polymerases, respectively. *In situ* hybridization was performed using techniques minimally altered from those published by Riddle et al.⁴⁸ and developed using BM purple AP substrate (Roche) per the manufacturer's instructions.

5 µm thick sections of paraffin embedded lung tissues were used for ISH of *Fgf10* (NM_446371, 862-1978 nt, Advance Diagnostic), *Fgf9* (NM_013518.4, 27-1198 nt), *Fgfr2* (NM_010207, 2-1677nt), and *Svep1* (NM_022814.2, 2879 -3726 nt) using RNAscope 2.0 Red Detection Kit (Advanced Cell Diagnostic) according to the manufacturer's instructions.

Immunohistochemistry. For the quantification of lung distal epithelial tips, fixed whole lungs were washed with PBS and permeabilized in 0.5% Triton-X, 5% BSA in PBS for 1 hr at room temp. SOX9 primary antibody diluted in 1X PBS was incubated overnight at room temperature. Samples were washed 3 times for 15 min in PBS. An Alexa fluor (Life Technology, USA) secondary antibody diluted in 1X PBS was incubated for 2 hr at room temperature. Samples were mounted with DAPI mounting medium. Samples were washed again before fixation with 4% PFA in PBS for 2–4 hr. Quantification was performed using ImageJ⁴⁹ and statistical significance was determined using a two-tailed t-test with significance at $p < 0.05$.

To evaluate branching patterns, fixed whole lungs from E13.5 embryos were dehydrated in a methanol series, washed with 20% DMSO in methanol, and then re-hydrated with a methanol series. Lungs were then permeabilized with 0.2% Triton-X in PBS, treated with Visikol Penetration Buffer for 2 hr, and then stored in Visikol Blocking Buffer overnight at 37° C. Primary antibodies were diluted in Visikol Antibody Buffer and lungs were incubated overnight at 37° C in the antibody mixture. Lungs were washed with Visikol Wash Buffer, then treated with secondary antibodies diluted in Visikol Antibody Buffer overnight at 37° C. Lungs were washed again with Visikol Wash Buffer, then dehydrated in a methanol series. Finally, the lungs were treated with Visikol HISTO-1 solution for 4 hr, followed by Visikol HISTO-2 solution for 4 hr. Lungs were mounted on slides using silicone-imaging chambers filled with Visikol HISTO-2 and imaged with a Keyence microscope. Z stack image series were generated for the whole lung

and used to create a video to trace the lineages of airway branches for orthogonal and planar bifurcation and for quantification of trifurcation and ectopic branching. Statistical significance was determined using a two-tailed t-test with significance at $p < 0.05$.

For whole mount lung explant branching immunofluorescence, fixed lungs from E12.5 embryos were placed in PBS overnight at 4° C, then dehydrated through a PBS/methanol gradient and bleached with 6% (vol/vol) hydrogen peroxide (H1009, Sigma) in methanol overnight at 4° C. The following day, samples were rehydrated in a methanol/PBS gradient, then blocked in PBS + 0.3% Triton X-100 + 5% normal goat serum for 2 hr, followed by addition of primary antibodies into blocking solution and incubated overnight at 4° C. Samples were then washed 3 times for 15 min with PBS + 0.1% Triton X-100 + 0.1% Tween-20, followed by addition of Alexa Fluor antibodies (Life Technology) diluted in PBS + 0.3% Triton X-100 at 4 °C overnight. Samples were mounted with DAPI mounting medium. Samples were washed again before fixation with 4% PFA in PBS for 2–4 hr.

Section Immunohistochemistry (IHC) was performed using standard techniques. Antigen retrieval was achieved by heat treatment in a microwave oven for 20 min at low power in 0.01 M sodium citrate buffer at pH 6. In tissues imaged using fluorescence, Alexa Fluor secondary antibodies were used (Life Technology). Images were obtained with a Nikon80i or Keyence microscope.

The following antibodies were used for IHC: anti- α -SMA (1:200; rabbit polyclonal; Abcam), anti- α -SMA (1:200; mouse polyclonal; Santa Cruz), anti-prosurfactant protein C (1:400; rabbit polyclonal; Abcam), anti-prosurfactant protein C (1:50; goat polyclonal; Santa Cruz), anti-Ki67 (1:50; rat monoclonal; Invitrogen), anti-CD31 (1:50; rabbit polyclonal; Abcam), anti-PDGFR- α (1:200; rabbit polyclonal; SantaCruz), anti-podoplanin (hamster monoclonal; Abcam) , anti-SOX9 (rabbit monoclonal; Abcam), anti-E-Cadherin (1:200; mouse monoclonal; Abcam), anti-E-Cadherin (1:100; rat monoclonal; Invitrogen), anti-ERG (1:50; rabbit monoclonal; Abcam), anti-FOXJ1 (1:200; mouse monoclonal; Santa Cruz), anti-SOX2 (rat monoclonal; Invitrogen), and Uteroglobin (rat polyclonal; Abcam).

Embryonic lung explant imaging. Lungs from E12.5 embryos were dissected and transferred to a Corning transwell cell culture well plate insert (Millipore Sigma) containing 2 ml of DMEM/F12 medium supplemented with 1 U/ml penicillin-streptomycin. Lung were incubated in the chamber and time lapse images were recorded every 10 min over 48 hr with a Keyence microscope. Time lapse videos were generated using the Keyence software.

Treatment of lung explant culture and morphometrics. Lung explants from E12.5 *Svep1*^{+/+} and *Svep1*^{-/-} embryos were treated for 2 days with a 146 amino acid SVEP1 peptide fragment from the Sushi or Complement Control Protein (CCP) module repeat domain 4 (WGAANRLDYSYDDFLDTVQETATSIGNAKSSRIKRSAPLS DYKIKLIFNITASVPLPDER NDTLEWENQQRLLQTLETITNKLKRTLNKDPMYSFQLASEILIADSNSLETKKASPFRCRPGSVLR GRMVCNCPGLGTYYNLEHFTCESC) produced in *E. coli*, as a recombinant protein antigen of

Svep1 (10 µg/ml, NP_0735725.2, region 874-971, Novus Biologicals) or for 2 to 4 days with an inhibitor of FGF signaling (2.5 µM SU5401, Pfizer).

The fold change of epithelial branches in lung explant cultures was determined by counting the starting number of individual branches at $t=0$, then counting new epithelial buds observed emerging from the lung epithelium throughout the time lapse experiment. Counting was performed manually using ImageJ. Lung buds were categorized as peripheral branches only if they appeared at the most distal end of the secondary bronchi. Epithelial area was measured using the Keyence software. The epithelial area of lungs was marked by setting a threshold value to separate the pixels of the lighter epithelial tissue from the darker mesenchyme tissue, with corrections by hand as necessary. Once a threshold was determined, the total area of the epithelium and the perimeter was then measured and recorded. Statistical significance was determined using a two-tailed t-test with significance at $p < 0.05$.

RNA isolation and double stranded cDNA synthesis. Total RNA was isolated from whole embryonic lungs at E18.5 using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. Double stranded cDNA was synthesized from total mice lungs RNA using the iScript™ cDNA Synthesis Kit from BIORAD following the manufacturer's instructions.

RNA-seq experiments and analysis. Library preparation and sequencing services were provided by Novogene Co. Ltd on the Illumina sequencing platform. RNA samples were processed by Novogene according to manufacturer instructions. The generated cDNA library was sequenced in 2 × 150 bp paired-end layout using Illumina HiSeq2500. Sequencing data were analyzed using the Galaxy web platform (<https://usegalaxy.org/>)⁵⁰. Sequence quality was assessed via FastQC (version 0.11.8)⁵¹. Sequence reads were aligned to the reference mouse genome (GRCm38) using STAR (default parameters, version 2.6.0b-1)⁵². Mapped reads were tallied using featureCounts Galaxy Version 1.6.4 (default parameters). Differential gene expression analysis was performed using DESeq2 (version 1.22.1)⁵³ in the R programming environment (version 3.5.1)⁵⁴. Pathway and function enrichment analysis on the differentially expressed genes was performed using metaspape (<http://metaspape.org>)⁵⁵. Results were visualized as an enrichment network and enrichment bar graph. Annotation enrichment analysis on the differentially expressed genes was performed with Visual Annotation Display (VLAD)⁵⁶ and with the Gene Ontology term enrichment tool (<http://geneontology.org/docs/go-enrichment-analysis/>).

Quantitative PCR. After obtaining cDNA, real-time PCR was performed with IQ SYBR Green Supermix (Biorad,) and gene-specific primers. The data were analyzed using the $\Delta\Delta C_t$ method on the BioRad CFX manager v1.5. RT-qPCR mRNA expression was analyzed by the Wilcoxon rank-sum under the hypothesis of $H_1 = a < b$. We reasoned H_1 as RT-qPCR assay followed protein cell counting in which we already predicted that $a < b$.

The following primer pairs were used for qPCR of mouse genes with *Actb* as the reference for normalization:

Sox9: 5' AGGAAGTCGGTGAAGAACGG3', 5'GGACCCTGAGATTGCCCAGA3'
Fgfr2: 5' TGTGCAGATGGGATTACCGT3', 5' ATTTGGTTGGTGGCTCTTCTG3'
Kras: 5'GATGTGCCTATGGTCCTGGTA3', 5'GCATCGTCAACACCCTGTCT3'
Fgfr2b: 5'AGCTCCAATGCAGAAAGTGC TGG 3', 5' GTTTGGGCAGGACAGTGAGCC 3';
Fgfr2c: 5' CCACGGACAAAGAGATTGAGG 3', 5' TGTCAACCATGCA GAGTGAAAG 3';
Actb: 5' CGGCCAGGTCATCACTATTGGCAAC3', 5' GCCACAGGATTCCATACCCAAGAAG3'.

scRNA-Seq single cell suspensions. To prepare the single cell suspensions, a pregnant, heterozygous female *Svep1* mouse (JAX 023814) was sacrificed at 18.5 days post coitum (dpc) by cervical dislocation (IACUC protocol 10100 to CJB). Embryos were removed from the uterine horn and transferred to dishes of warm (37°C) 1X Delbecco's Phosphate Buffered Saline (DPBS; ThermoFisher, 14190250) and euthanized by decapitation. Tail tips from each embryo were collected for genotyping analysis. The distal tip of the right caudal lung lobe from each embryo was resected and transferred to individual wells of a 12 well plate. The methods for single-cell suspension preparation were adapted from Sekiguchi and Hauser⁵⁷. Each tip was submerged in a cold solution of 40 µL of 1.6 U/mL dispase II (ThermoFisher, 17105041) and 40 µL Dulbecco's Modified Eagle Medium (DMEM)/F12 (ThermoFisher, 11039021) and incubated for 10 minutes at 37°C and 5% CO₂. After incubation, dispase was inactivated by adding 80µL of cold DMEM/12 supplemented with 5% bovine serum albumin (BSA; Sigma-Aldrich, A8577) into each well. The lung tissues were then transferred into individual wells of a new 12 well dish, each well of which contained 80µL of calcium and magnesium free Hanks' Balanced Salt Solution (HBSS, ThermoFisher, 14170112) to rinse off the media. Individual tissue pieces were then transferred to separate 1.5 mL microcentrifuge tubes (USA Scientific, 1415-2500), each containing 80µL protease mix (4.5µL/mL Accutase; Stem Cell Technologies, 07920; 4.5 µL/mL Accumax; Stem Cell Technologies, 07921, and 0.1mg/mL *Bacillus licheniformis* protease; Creative Enzymes, NATE0633, in calcium/magnesium-free DPBS). Samples were gently agitated with a pipet to dissociate for 2 minutes. Samples were then incubated on ice for 15 minutes before addition of 920µL calcium and magnesium free DPBS supplemented with 10% filtered Fetal Bovine Serum (FBS, Millipore Sigma). The samples were then filtered using Flowmi 40-um strainers (Bel-Art, H13680-0040) into individual Corning 15-mL tubes. 500µL of DPBS plus 10% FBS was added to each sample and samples were centrifuged at 112xg for 7 minutes at room temperature. Supernatants were carefully removed and cell pellets were each washed with 1mL of calcium and magnesium-free DPBS plus 1% FBS. Samples were centrifuged at 112xg for 4 minutes at room temperature then all but 40-50 µL of each supernatant was removed.

Following filtration, single cell suspensions from two mutant and two wild type *Svep1* embryos were immediately washed and resuspended in PBS containing 0.04% BSA and cells were counted in a Countess II automated cell counter (ThermoFisher). From each sample, 12,000 cells were loaded into one lane of a 10X Chromium microfluidic chip. Single cell capture, barcoding, and library preparation were performed using the 10x Chromium version 3 chemistry kit according to the manufacturer's protocol (#CG00183). Quality checks for cDNA and libraries were conducted on an Agilent 4200 TapeStation. The cDNA and libraries were then quantified

using KAPA Biosystems qPCR (Sigma-Aldrich) and sequenced using Novaseq6000 (Illumina) to an average depth of 50,000 reads per cell.

scRNA-seq library preparation and quality control. Raw sequencing files were demultiplexed and FASTQ files were generated using the Cell Ranger analysis pipeline from 10x genomics (<https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/what-is-cell-ranger>). Sequencing reads with mismatches within the eight-base i7 Index 1 were filtered out. The remaining libraries were aligned to the mouse reference genome assembly (GRCm38.p6) using STAR⁵². Sequence reads with MAPQ scores less than 255 or containing bases with Q30 scores below 3 were removed. Following alignment, the cell bar codes were mapped to a list of 737,500 barcodes from 10X Genomics, with one allowed mismatch. Cell barcodes associated with a unique molecule identifier (UMI) count lower than the threshold were assumed to be related to ambient mRNA and were filtered out. A count matrix of the remaining cells and their associated genes was generated by CellRanger (10X Genomics) and used for downstream analysis. A total of 6,864 cells from mutant samples and 12,309 cells from the wild type *Svep1* controls were characterized with 31,053 raw genes.

The Seurat R package was used to analyze the data^{58; 59 60; 61}. Each replicate and experimental group was analyzed prior to aggregation to check the quality of cells and cell populations. Within each of the replicates, cells were filtered based on mitochondrial RNA content, UMI counts, and high/low gene counts. To normalize RNA counts in each cell, RNA that mapped to the mouse genome was divided by total RNA counts for each cell, then scaled by a factor of 10000 and log transformed. After feature RNA normalization, replicates were aggregated into the two experimental groups.

scRNA-seq data processing. The two experimental groups were aggregated separately and scaled to account for batch effects between replicates. Linear regression was used to scale all 31,053 genes to preserve expression variance of low abundance genes from small populations of progenitor cells. Principal Component Analysis (PCA) was conducted to establish 80 principal components. Random resampling using Seurat's jackstraw function was used to calculate the significance of each PC^{62; 63}. Clustering of cells was determined using the Jaccard index between each cell and its k-nearest neighbors. For the final dimension reduction step, Uniform Manifold Approximation and Projection (UMAP) was applied to the samples to project the data onto low-dimensional and easily visualized space while conserving global relationships⁶⁴. Marker genes for each cluster were determined by running differential expression analysis using the Wilcoxon Rank Sum test on each cluster. To determine the cell types of each cluster, iterations of the 15, 20, 25, and 30 most upregulated genes from each cluster were mapped to a lung cell population markers dataset curated from CellMarker and LungGENS^{65; 66}. Clusters were labeled with the cell type according to the most upregulated genes associated with the cell type markers. The cell populations of each experimental group were visualized using UMAP.

The two normalized data sets were then merged using nearest neighbor cell pairs between the two experimental groups, or anchors, to ensure that similar cells from each group

were mapped closely^{61; 67}. Scaling, PCA, clustering, and UMAP dimension reduction analysis for the integrated data set were conducted in the same manner as the individual sample sets.

Segregation of mutant cells in various populations. To determine the cell populations most impacted by the loss of *Svep1*, the distribution of cell populations in each experimental group was determined by calculating the ratio of each Seurat cluster to total number of cells from an experimental group. A t-test of the ratios was conducted to determine populations significantly enriched or depleted in the mutant tissue. Clusters demonstrating a segregation between mutant and wild type origin cells were compared to the nearest-related clusters using the Wilcoxon Rank Sum test for differential gene expression.

Differential gene expression and annotation enrichment for scRNA-Seq. Differential gene expression was defined as genes with a p-value < 0.05 expressed in at least 25% of the analyzed populations, and $-0.25 > \log \text{ fold change} > 0.25$. Differentially expressed gene sets were submitted to the Visual Annotation Display (VLAD)⁵⁶ software to perform annotation enrichment analysis for Mammalian Phenotype and Gene Ontology annotations.

Results

Svep1 is expressed in the lung mesenchyme with high expression at the lung periphery. To determine when and where *Svep1* is expressed during lung development, we performed immunohistochemistry and *in situ* hybridization of *Svep1* at E12.5, E14.5, E16.5 and E18.5. During the pseudoglandular stage (E12.5–E16.5), *Svep1* mRNA and protein expression were observed in the mesenchyme, especially at the tip and edges of the lung (Fig. 1A-C). *Svep1* gene expression was strong adjacent to the distal epithelial airways and around bifurcating tips (Fig. 1A). SVEP1 protein labeling was observed at the distal airway epithelia buds, at bifurcating points, and in the developing microvasculature (Fig. 1C). In E12.5 (data not shown) and E14.5 lungs, we observed some SVEP1 protein adjacent to the epithelial membrane of very distal buds, co-localized with ECAD (Fig. 1B). At the saccular stage (E18.5), *Svep1* mRNA and protein were localized in the primary septa of lung parenchyma and adjacent to the proximal epithelium (Fig. 1D). Consistent with previous findings, *Svep1* expression during lung development was highest between E14.5 and E18.5⁶⁸.

Lungs of Svep1 knockout mice are hypoplastic and have abnormal lobes, a hypercellular mesothelium, and small sacculles. Consistent with previous reports, *Svep1*^{-/-} embryos displayed perinatal lethality, whole-body edema, and lung hypoplasia that was prominent at E18.5 by microCT (Fig. 1E)⁴⁴. The absence of *Svep1* expression in the lungs of homozygous knockout animals was confirmed by *in situ* hybridization (data not shown). The ventral side of the lungs of *Svep1*^{-/-} embryos at E18.5 had small and rounded lobes that failed to surround the heart and the lung surface in that region was heavily lobulated giving the lung lobes a cauliflower-like appearance (Fig. 1F). Histological analysis of the lungs of mutant mice showed that the lung surface had a serrated appearance by E14.5 and lungs were obviously hypoplastic by E16.5 (Fig. 1G). At E18.5, the lungs of *Svep1* mutants exhibited small sacculles along a dorsal-ventral

gradient, with a reduced lumen primarily on the lobulated ventral side of the lung (Fig. 1H). Lungs of *Svep1*^{-/-} embryos exhibited a hypercellular mesothelium (Fig. 1H).

Saccular development begins in the murine lung shortly after E16.5, with the flattening of pneumocytes and the proximal-to-distal opening of the distal airway lumen. At the lung edge, distal airways are the last to differentiate. These distal airways retain a progenitor state and remain closed^{28; 69}. To examine airway morphology, we labeled the lung epithelium with both ECAD (*Cdh1*; MGI:88354) and the distal progenitor marker, SRY-box 9 (*Sox9*; MGI:98371). The images showed multiple, densely packed distal airways in the distal tip in E16.5 mutant lungs (Fig. 1G). Labeling at E18.5 demonstrated that the distal airway epithelium in the lobulated *Svep1*^{-/-} lungs retained a typical pseudoglandular stage epithelial cuboidal form and expressed high levels of SOX9 (Fig. 1H). KI67 staining confirmed that the SOX9+ cells were actively proliferating (data not shown). Quantitative real-time PCR (qPCR) also confirmed a significant increase of *Sox9* expression in the lungs of *Svep1* knockout embryos at E18.5 (data not shown).

*Lungs of *Svep1*^{-/-} embryos are characterized by an aberrant increase and disorganization of distal airways which affects the shape of lung lobes.* We used immunofluorescence imaging with SOX9 to evaluate the distal airways in individual lung lobes of *Svep1* wild type and mutant embryos from E13.5 and E14.5 (Fig. 2A-D). We found branching and lobe shape anomalies in *Svep1*^{-/-} lungs as early as E13.5, primarily at the lung tips and edges, which became more severe as lung development progressed. The lobe shape anomalies were more pronounced in the Right caudal (RCa) lobes compared to the other lobes in *Svep1*^{-/-} embryos (Fig. 2A). The Right Accessory (RAc) lobe, which normally ends in a single tip around E13.5, often terminated in two or more airways in the lungs of mutant embryos. The accessory lobes in mutant were shorter than in wild type embryos (Fig. 2A). We also observed secondary ectopic lateral budding in the RAc lobe of the mutants (Fig. 2B).

During normal planar bifurcation single distal tips flatten, form a cleft, and then bifurcate into two daughter branches⁴. According to our findings at E13.5, *Svep1* deficiency caused branching anomalies in the lung edges and tips, including mis-localized and extra budding (Fig. 2A,B). In contrast to typical pointed lobes in wild type mice, the left lobes in mutant embryos are wider due to aberrant distal tip patterns which appear to be caused by defects in the branching angles (Fig. 2C).

The orthogonal bifurcation mode of the branching program fills the lung's interior in a specific pattern and creates the lobe surface of the lung lobes⁴. In lungs of mutants at E14.5, the airways were rearranged in a "row of beads" pattern leading to abnormal rounded tips (Fig. 2C). In addition, the left lung lobes of mutant embryos were 8% longer than wild type *Svep1* embryos ($p < 0.001$ t-test). Whole left lobes cleared and labeled with SOX9 at E14.5 confirmed abnormal mutant left lobe morphology due to distal airway multi-budding and peripheral trifurcations (Fig. 2D). Defects in branching were also reflected in the significant increase in the number of distal tips SOX9+ at E14.5 (Fig. 2E; $p < 0.05$ t-test). Taken all together, these results

suggest that *Svep1* plays a critical role the branching program and determines the architecture of the bronchial tree and consequently, the shape of lung lobes.

Lungs of Svep1^{-/-} embryos have ectopic branching, decreased bifurcations, and increased trifurcations. To determine which of the main branching programs are distorted in *Svep1* mutants, we modeled the branching patterns of normal and mutant lungs. To study the structure of the airway epithelium at E14.5, we labeled tissue-cleared whole lungs with ECAD and SOX9 and generated a 3D reconstruction composed of Z-stack images. Our findings revealed significant structural differences in the airways of wild type and *Svep1^{-/-}* lungs, confirming the duplication of the distal airway at the lobe tip as well as the disorder of the whole airway tree (Fig. 3).

To quantify differences in branching morphology in mutant vs wild type embryos we generated a branching lineage diagram for the right accessory (RAc) lobe at E14.5. Each branch was characterized as one of three branching modes: domain, planar, or orthogonal⁴. Branches and direction of growth were mapped to create a lineage diagram with trifurcations indicated (Fig. 3B). Orthogonal branching was significantly increased in mutants, contributing 63% of all branches compared to the 49.19% ($p < 0.01$, t test) in the lungs of *Svep1^{+/+}* embryos. In contrast, the planar branching in the RAc was significantly decreased in mutant (5%) compared to normal (13%) embryos ($p < 0.05$, t test). An average of 17% of first-level domain branches originating from the primary bronchus were ectopic in *Svep1^{-/-}* lungs, while no ectopic branching was observed in the lungs of wild type embryos (Fig. 3D). Trifurcations were more prevalent in *Svep1^{-/-}* lungs (10% of all branches) compared to the lungs of *Svep1^{+/+}* embryos (4% of all branches) ($p < 0.05$ t test; Fig. 3C). In RAc lobes of normal lungs, daughter branches of the primary bronchus sprouted from one of only three directions: anterior, ventral-posterior, and dorsal-posterior⁴. In all the *Svep1^{-/-}* lungs analyzed, daughter branches sprouted from the primary bronchus in random directions (Fig. 3D).

To determine if the ectopic and trifurcated branches in *Svep1^{-/-}* lungs was the result of loss of *Svep1*, we analyzed time-lapse images of E12.5 lung explants for 48 hr (Fig. 3E). We observed ectopic branching arising from the main and secondary branches and numerous trifurcations at the lung tips. From this data we conclude that *Svep1* plays a role in determining the location and branching mode of new airway epithelial buds, which affects the shape and structure of the airway epithelium in the developing lung.

Single Cell RNA sequencing (scRNA-seq) of the distal lung identifies cell populations depleted in mutant mice. To investigate sacculle development and its effect on cell populations and pathways in lung development, we conducted single cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq) on the distal tip of right caudal lobe from wild type and mutant embryos at E18.5. We isolated 6,864 cells from mutant samples and 12,309 cells from the wild type *Svep1* controls, characterized with 31,053 genes. After performing quality control and merging the individual single cell sequencing data sets, we conducted scaling of the total data set using a linear transformation to preserve the expression patterns of genes with low levels of global expression. UMAP analysis of the top 80 Principal Components revealed 24 cell clusters

representing 11 cell types: matrix fibroblast cells, type I pneumocytes, type II pneumocytes, smooth muscle cells, ciliated cells, pericytes, myeloid cells, fibroblasts, epithelial cells, endothelial cells, and club cells (data not shown). *Svep1* is expressed predominantly in matrix fibroblast cell populations. Analysis of functional annotation terms for differentially expressed genes between the lungs of *Svep1*^{+/+} and *Svep1*^{-/-} embryos from both bulk and scRNA Seq data revealed an enrichment of biological process and phenotype terms associated with cell mobility and adhesion, vasculature development, and extracellular matrix formation (data not shown). These findings are consistent with previous studies on phenotypes observed in mice as a consequence of the loss of *Svep1* function in a variety of tissues and cell types^{39-41; 70}.

Svep1 is necessary for alveolar epithelial cellular differentiation and maturation. The small or absent saccules in mutants and the increase of SOX9+ cells (Fig. 1H), suggest that a persistent branching program in *Svep1* mutants is blocking normal alveolar differentiation. Lung sections stained with toluidine blue at E18.5 revealed a high density of round type II pneumocytes, small saccules, and a reduced expression of surfactant proteins in the lungs of *Svep1*^{-/-} embryos (Fig. 5A). Notably, scRNA Seq data revealed that type I pneumocytes (AT1) cells represented 5.1% of the total cell composition in the lungs of *Svep1*^{+/+} embryos, but only 2% of the total population for the lungs of *Svep1*^{-/-} embryos (data not shown). Genes associated with type 1 pneumocytes (AT1) were found to be significantly lower in the lungs of *Svep1*^{-/-} mutant embryos (4B) whereas genes associated with type II pneumocytes (AT2) were upregulated (Fig. 4B). To evaluate type I pneumocyte development in the developing lung, we labeled E18.5 lungs with type 1 pneumocyte markers PDPL and HOPX (4C,D). In *Svep1*^{-/-} embryos, PDPL and HOPX1 positive domains were reduced by E16.5 (data not shown) and in the small alveolar saccules at E18.5 (Fig. 4C,D). These findings suggest that in the absence of *Svep1*, the alveolar epithelium cannot differentiate and mature correctly.

The loss of Svep1 leads to defects in smooth muscle in the lung. Several muscle development related genes were significantly downregulated in the lungs of *Svep1*^{-/-} embryos (Fig. 5A), including *Acta2* (actin 2; MGI:87909) which is necessary for smooth muscle differentiation. *Cnn1* (calponin1; MGI:104979), a marker for mature smooth muscle, was also downregulated in mutants (Fig. 5A). Lungs labeled with ACTA2 at E18.5 confirmed the reduction in distal bronchioles in the mutant lung at E16.5 (Fig. 5B). Blood vessels adjacent to the conductive airways also showed a reduction in ACTA2 labeling in the lungs of *Svep1*^{-/-} embryos (Fig. 5B). Defects in smooth muscle differentiation and airway formation were confirmed by *ex vivo* organ culture of E12.5 *Svep1*^{-/-} when lung explants were allowed to grow *in vitro* for six days (Fig. 5C). The expression of ACTA2 in the explant cultures was noticeably reduced in mutants, particularly in lobular bronchioles.

Alveolar myofibroblasts are ACTA2 positive cells that transiently differentiate from their PDGFRA (MGI:97530) positive progenitors during septation⁷¹. During normal murine lung development, PDGFRA progenitors are located at the base of saccules in the regions of future alveoli and migrate toward the saccule lumen⁷². Immunofluorescence of PDGFRA and ACTA2 positive cells revealed a deficiency in alveolar myofibroblast (ACTA2+), but not in their progenitors (PDGFRA+), in the lungs of E18.5 *Svep1*^{-/-} embryos (Fig. 5D). Quantification of

PDGFRA+ cells revealed that the average number of PDGFRA+ cells was higher in lungs of *Svep1*^{-/-} embryos at E18.5 compared to wild type (*Svep1*^{+/+} = 115.8 ± 7.1; *Svep1*^{-/-} = 178.3 ± 23.0; p < 0.05 t-test). Also, the ratio of ACTA2+ to PDGFRA+ cells was lower (*Svep1*^{+/+} = 49.2 ± 2.2; *Svep1*^{-/-} = 29.2 ± 4.8; p < 0.05 t-test) in mutants (Fig. 5E). No significant differences in the expression of *Pdgfra* in mutant and wild type lungs were detected in the RNA Seq data. However, *Pdgfra* (MGI:97527) expression was reduced in *Svep1*^{-/-} embryos at E18.5 (Log2(FC) = -0.19318, adjusted p value < 0.05). PDGFA signals through PDGFRA and is involved in myofibroblast proliferation and migration^{73; 74}. *Pdgfra*+ cells give rise also to alveolar lipofibroblasts that are characterized by their lipid-filled vesicles^{75; 76}. We looked at the expression of *Plin2* (perilipin 1 -- aka *adipophilin*; MGI:87920) in the RNA Seq data to determine if alveolar fibroblast development was biased toward lipofibroblast development but there were no significant differences in expression for this gene between mutants and wild type lungs at E18.5. These data are consistent with the hypothesis that *Svep1* is required for differentiation of smooth muscle cells, particularly in the distal lung, beginning early in lung development.

Conductive airways in *Svep1*^{-/-} embryos are hypoplastic and enriched in basal cells. Club cells are secretory cells abundant in terminal bronchioles as a source of progenitors capable of differentiation into ciliated and goblet cells during normal lung development¹¹. The scRNA Seq data indicated that the cluster of Club cells was enriched in cells from *Svep1* mutants relative to wild type (data not shown). To determine mutant defects in epithelial airways differentiation, we labeled the proximal epithelium with the club cell marker, Secretoglobin 1a1 (*Scgb1a1*; MGI:98919), and a marker of ciliated cells, Forkhead box protein J1 (*Foxj1*; MGI:1347474) (Fig. 6A). *Svep1*^{-/-} embryos labeled with SCGB1A1 displayed a hypoplastic distal airway with a narrow lumen compared to controls (Fig. 6A). The bronchioles in mutant embryos were hypercellular and often displayed a disorganized epithelium (Fig. 6A). At E18.5, most epithelial cells in distal bronchioles of normal murine lungs are non-ciliated cuboidal cells positive for SCGB1A1⁷⁷. We quantified the total number of SCGB1A1+ and FOXJ1+ cells and calculated the ratio of these cells in the terminal bronchioles of normal and mutant lungs. The number of SCGBA1+ cells was significantly increased in mutants, but the total number of FOXJ1+ cells and the ratio between SCGBA1+ and FOXJ1+ were not statistically significant (Fig. 6B). The expression of *Scgba1* in mutants did not differ from that of wild-type mice (data not shown).

Svep1^{-/-} lungs exhibit disorganized vasculature and mesothelial immaturity. Both the scRNA Seq and bulk RNA Seq data revealed that the lungs of *Svep1* knockout embryos have decreased expression of vascular development regulators including annexin A1 (*Anxa1*; MGI:96819) and chitinase like-1 (*Chil1*; MGI:12654). These results are consistent with previous work showing the role of *Svep1* in vascular development and remodeling in the mouse^{40; 41}. In addition, the cluster of pericyte cell type from the scRNA Seq data were depleted of mutant cells (data not shown). Annotation enrichment analysis also indicated that pathways associated with vascular function were disrupted in the mutants (data not shown). To determine if the lung microvasculature formation is affected in *Svep1*^{-/-} lungs, we labeled E18.5 endothelial cells with the nuclear marker ETS-related gene (*Erg*; MGI:95415) (Fig. 6C). The microvasculature in the lungs of mutant embryos was disorganized and failed to form the double layer pattern characteristics of the saccular stage (Fig. 6C).

The lungs are covered by a monolayer of progenitor mesothelial cells that are round and smooth and flatten when differentiated⁷⁸. We observed that lungs from *Svep1*^{-/-} embryos at E18.5 had hypercellular edges and labeled lungs with the mesothelial progenitor marker Wilms' tumor suppressor 1 (*Wt1*; MGI:98968) (Fig 6D). Labeling with WT1 showed that the rounded lung lobes observed in mutant embryos were covered with mesothelial progenitors. The RNA Seq data showed that expression of *Wt1* was higher in the lungs of the mutants (Fig. 6D,E). To determine if the increase of mesothelial cells was due to an increase in cellular proliferation, we co-labeled with WT1 and KI67 (aka Mki67; MGI:106035) (Fig. 6F). There was a significant increase in the number of WT1+ cells in *Svep1*^{-/-} lungs (*Svep1*^{+/+} = 43.0 ± 7.0; *Svep1*^{-/-} = 72.8 ± 39.6; p < 0.05 t test). However, the percentage of WT1+ that were also KI67+ was not significantly different between normal and mutants at E18.5 (*Svep1*^{+/+} = 14.9 ± 0.4; *Svep1*^{-/-} = 13.1 ± 0.6) (Fig. 6E). This ratio was also not statistically different at E16.5 (*Svep1*^{+/+} = 25.2 ± 0.9; *Svep1*^{-/-} = 27.5 ± 4.4). These results suggests that mesothelial differentiation is disrupted in mutants and that the observed phenotype is not due to increased proliferation.

SVEP1 acts as a negative regulator of branching morphogenesis. The increased branching observed in the distal airways of *Svep1*^{-/-} embryos suggests that SVEP1 normally acts as a negative regulator of lung branching morphogenesis and is essential for regulating lung airway budding. To investigate the function of *Svep1* in branching morphogenesis further, we treated lung explants from *Svep1*^{-/-} and wild type E12.5 embryos for 48hr with a recombinant SVEP1 (rSVEP1) protein. Time lapse images revealed decreased branching in the treated lung explants (Fig. 7A). Quantification of peripheral branches revealed a significant decrease in branching at the tips of the lungs (Fig. 7B). Additional morphometric analysis revealed a much reduced epithelial area, a significantly decreased epithelial width, and an increase in bud elongation in E12.5 lung explants from *Svep1* mutants (data not shown). When lung explants from E12.5 *Svep1*^{-/-} embryos were treated with rSVEP we observed a dramatic reduction of ectopic and trifurcated branches; distal trifurcations were observed in only one of the six explants treated with rSVEP1 (Fig. 7C).

*Branching patterning defects, but not smooth muscle differentiation, in *Svep1*^{-/-} embryos are independent of the FGF pathway.* Given the abnormal branching and the bulk RNA Seq data which revealed a significant upregulation in the expression of *Fgfr2* in *Svep1*^{-/-} lungs at E18.5 (Log2(FC) = - 0.722; P. value adj= 6.66E-13), we investigated whether the FGF pathway is involved in the abnormal lung branching phenotype in *Svep1*^{-/-} mutants. *Fgfr2* is normally expressed in the lung epithelium with a decrease in expression after E17.5⁶⁸ In *Svep1*^{-/-} embryos however, *in situ* hybridization showed that levels of expression of *Fgfr2* persisted in the lungs of mutants even at E18.5 compared to levels in *Svep1*^{+/+} lungs (Fig. 7D). Although the expression of *Fgf9* and *Fgf10* was not significantly increased in E18.5 lungs of mutants based on bulk RNA Seq or scRNA Seq experiments (data not shown), RT-qPCR results showed a significant increase of *Fgfr2* (MGI:95523), *Fgf10* (MGI:1099809), *Fgf9* (MGI:104723), and *Kras* (MGI:96680) in the lungs of *Svep1* mutants E18.5 (Fig. 7E) but not at E14.5 or E16.5 (data not shown). *Fgfr2* has two isoforms, *Fgfr2b* and *Fgfr2c*. Only the transcript abundance of *Fgfr2b* was significant at E18.5 (Fig. 7E).

The airway smooth muscle in the lung develops from local mesenchymal cells located around the tips of growing epithelial buds. These cells become gradually displaced from distal to a proximal position alongside the bronchial tree, where they elongate, and begin to synthesize smooth muscle-specific proteins⁷⁹. FGF10+ cells serve as progenitors to parabronchial smooth muscle cells and this progenitor status is maintained by mesothelial-derived FGF9 which has been shown to inhibit smooth muscle differentiation in the mouse lung^{80; 81}. To investigate the involvement of the FGF pathway in *Svep1*^{-/-} branching defects and smooth muscle differentiation further, we treated lung explants with the FGF pathway inhibitor SU5402 at a dose low enough to allow some branching activity. As expected, we observed some branching inhibition in the control and *Svep1*^{-/-} lung explants after 48 hr of treatment (Fig. 7F). However, immunofluorescence of ACTA2 and SOX9 revealed distal trifurcations and first branch ectopic branching in *Svep1*^{-/-} lungs (Fig. 7F). Lung explants treated with SU5402 for four days showed expanded ACTA2 localization encapsulating the distal airways of control and *Svep1*^{-/-} lungs, as previously observed^{81; 82}, but less so in mutants (Fig. 7G). Overall, these results indicate that the branching pattern defects in *Svep1* mutants are independent of the FGF pathway, but that smooth muscle defects are, in part, mediated by increased FGF signaling in *Svep1* mutants.

Discussion

Many previous studies of mammalian lung development have generated insights into the genetic and molecular processes that underlie lung branching morphogenesis and alveolarization. However, the factors that regulate the bronchial tree's stereotyped structure and the subsequent transition from branching to saccular formation are still unclear. This transition is essential for establishing the developmental foundation for alveologenesis and has significant clinical ramifications for neonates born with such respiratory deficiencies as lung hypoplasia. The study reported here demonstrated, for the first time, that the extracellular matrix gene, *Svep1*, is necessary for ending lung branching morphogenesis and that the loss of *Svep1* impairs alveolar maturation and differentiation.

Key findings of this study are that *Svep1* is essential for normal lung branching and acts as a negative regulator of branching. In *Svep1*^{-/-} embryos on a C57BL/6J inbred background, abnormalities of the lung structure were obvious by E13.5 and became progressively worse over the course of development. *Svep1* is normally highly expressed in the mesenchyme of bifurcating peripheral lung tips during branching and these regions were most impacted by the loss of *Svep1*. The absence of *Svep1* led to marked lung hypoplasia but with a concomitant increase in branching in the distal airways. Normally, lung buds tend to fill the mesenchyme homogeneously in an orderly and non-conflicting or overlapping pattern⁵. The lungs of *Svep1*^{-/-} embryos, however, were characterized by ectopic branching, decreased bifurcations, and increased trifurcations which resulted in an increased number of disorganized distal airway tips and a disruption in the shape of the lung lobes. A 3D reconstruction of the right accessory (RAc) lobe revealed that the abnormal trifurcations in the branching results in a pattern of dense rosettes in the distal airways. This branching defect is most likely responsible for the cauliflower-like appearance of *Svep1*^{-/-} lungs. The impact of the loss of *Svep1* was different for different

lung lobes. Lobes with wide flat tips, such as the right caudal (RCa) and right cranial (RCr) lobes, were more elongated with rounded edges in the mutants compared to the lobes from wild type embryos which were flat at the edges and terminated pointed tip. The RAc lobe and right medial (RMe) lobe were foreshortened in mutants with rounded tips, presumably a consequence of increased and disorganized distal branching.

As FGF signaling is known to be essential for branching morphogenesis⁸³ we investigated the impact of inhibiting FGF signaling in lung explant cultures. Lungs from *Svep1*^{-/-} embryos continued to exhibit distal airway trifurcation in absence of FGF, demonstrating that the action of *Svep1* on branching is independent of FGF signaling. The abnormal branching phenotype in the lungs of *Svep1*^{-/-} embryos was reversed by treating E12.5 lungs for 24 hours in organ culture with recombinant SVEP1 protein. Inhibition of SOX9, which is downstream of SVEP1, also resulted in marked reduction of abnormal branching (data not shown).

In addition to the lung branching defects in *Svep1* mutants we observed defects in airway smooth muscle and microvasculature. *Svep1* has been shown previously to be involved in the early steps of myoblast differentiation and epidermal differentiation^{39; 84}. Our results suggests that *Svep1* plays a role in the direct regulation of smooth muscle differentiation in the lung supported by the transcriptomics data that revealed a significant downregulation of a number of smooth muscle genes in the lungs of mutant embryos. The microvasculature in the lungs of mutant embryos was disorganized and failed to form the double layer pattern characteristics of the saccular stage. The results are consistent with prior work demonstrating the role of *Svep1* in vascular system development and remodeling^{40; 41}.

Another key finding of this study is that the lungs of *Svep1* mutants exhibit impaired cellular differentiation. Embryos that lacked functional *Svep1* died shortly after birth due to severe saccular defects. The lumens of the distal airways at E18.5 were reduced and had cell morphology more typical of the pseudoglandular stage. These cells also showed extensive positive labeling for SOX9+ progenitor cells. Differentiation of the distal epithelial was observed in the *Svep1* mutant lungs but demonstrated a bias for type II (AT2) pneumocytes. These type II pneumocytes may have arisen from the proliferative SOX9⁺ cell population which, in turn, might be maintained by the abnormal persistent expression of genes involved in FGF signaling in *Svep1* mutants. *Svep1*^{-/-} lungs were deficient in type I (AT1) pneumocytes that arise from the HOPX⁺ and PDPL⁺ region near the stalk of the lung bud. Mesothelial cells at E18.5 in *Svep1*^{-/-} were also maintained in a progenitor state as evidenced by extensive positive labeling with the progenitor marker, WT1, and high expression of *Wt1* in mutants compared to controls.

The results of the present study clearly demonstrate the importance of the extracellular matrix in branching patterning and alveolar cellular differentiation in the lung. Disruption of the extracellular matrix has been shown previously to be detrimental to cellular differentiation processes⁸⁵, but this is the first report of the role that *Svep1* plays in orchestrating the transition from branching programs to alveolar differentiation. Additional investigation into the specific role that *Svep1* plays during the saccular phase to prepare the lung for alveologenesis will be required to understand the detailed molecular and cellular mechanisms of this transition. Based

on the observations in this study, we posit that SVEP1 peptides or inhibition of SVEP1 downstream targets such as SOX9 and members of the FGF signaling pathway could be useful approaches for treating lung prematurity. Dosage and timing of such interventions would need further study to determine regimens that reduce branching and simultaneously enhance differentiation and alveolarization. Studies of genes which, when disrupted, lead to congenital diaphragmatic hernia with a lung phenotype, could also be exploited to uncover therapeutics for treatment of respiratory anomalies characteristic of lung prematurity without CDH. Therapeutic modulation of the ECM may also open up new therapeutic avenues for treating lung damage arising from chronic obstructive pulmonary disease (COPD) or Covid19 infection where restoration of the regenerative capacity of the lung would be transformative in improving patient outcomes.

Acknowledgements

The authors thank Drs. Martin Ringwald and Vidhya Munnamalai for their comments on an early draft of this manuscript. Sandy Daigle (The Jackson Laboratory) provided essential technical support and advice for the scRNA Seq experiment. Pete Finger (The Jackson Laboratory) performed the toluidine blue staining.

Funding

Funding was provided by the National Institute of Child Health and Human Development (NICHD) P01HD068250.

References

1. Rawlins, E.L. (2011). The building blocks of mammalian lung development. *Dev Dyn* 240, 463-476.
2. Chang, D.R., Martinez Alanis, D., Miller, R.K., Ji, H., Akiyama, H., McCrea, P.D., and Chen, J. (2013). Lung epithelial branching program antagonizes alveolar differentiation. *Proc Natl Acad Sci U S A* 110, 18042-18051.
3. Warburton, D., El-Hashash, A., Carraro, G., Tiozzo, C., Sala, F., Rogers, O., De Langhe, S., Kemp, P.J., Riccardi, D., Torday, J., Bellusci, S., Shi, W., Lubkin, S.R., and Jesudason, E. (2010). Lung organogenesis. *Curr Top Dev Biol* 90, 73-158.
4. Metzger, R.J., Klein, O.D., Martin, G.R., and Krasnow, M.A. (2008). The branching programme of mouse lung development. *Nature* 453, 745-750.
5. Blanc, P., Coste, K., Pouchin, P., Azais, J.M., Blanchon, L., Gallot, D., and Sapin, V. (2012). A role for mesenchyme dynamics in mouse lung branching morphogenesis. *PLoS One* 7, e41643.
6. Zhao, X., Ju, Y., Liu, C., Li, J., Huang, M., Sun, J., and Wang, T. (2009). Bronchial anatomy of left lung: a study of multi-detector row CT. *Surg Radiol Anat* 31, 85-91.
7. Rawlins, E.L., Clark, C.P., Xue, Y., and Hogan, B.L. (2009). The Id2+ distal tip lung epithelium contains individual multipotent embryonic progenitor cells. *Development* 136, 3741-3745.
8. Frank, D.B., Penkala, I.J., Zepp, J.A., Sivakumar, A., Linares-Saldana, R., Zacharias, W.J., Stolz, K.G., Pankin, J., Lu, M., Wang, Q., Babu, A., Li, L., Zhou, S., Morley, M.P., Jain, R., and Morrissey, E.E. (2019). Early lineage specification defines alveolar epithelial ontogeny in the murine lung. *Proc Natl Acad Sci U S A* 116, 4362-4371.

9. Yang, Y., Fu, Q., Liu, Y., Wang, X., Dunham, R., Liu, S., Bao, L., Zeng, Q., Zhou, T., Li, N., Qin, Z., Jiang, C., Gao, D., and Liu, Z. (2018). Comparative transcriptome analysis reveals conserved branching morphogenesis related genes involved in chamber formation of catfish swimbladder. *Physiol Genomics* 50, 67-76.
10. Conway, F.M., Garner, J.L., Orton, C.M., Srikanthan, K., Kemp, S.V., and Shah, P.L. (2019). Contemporary Concise Review 2018: Lung cancer and pleural disease. *Respirology* 24, 475-483.
11. Rock, J.R., and Hogan, B.L. (2011). Epithelial progenitor cells in lung development, maintenance, repair, and disease. *Annu Rev Cell Dev Biol* 27, 493-512.
12. Herriges, M., and Morrissey, E.E. (2014). Lung development: orchestrating the generation and regeneration of a complex organ. *Development* 141, 502-513.
13. Whitsett, J.A., Kalin, T.V., Xu, Y., and Kalinichenko, V.V. (2019). Building and Regenerating the Lung Cell by Cell. *Physiol Rev* 99, 513-554.
14. Morrissey, E.E., and Hogan, B.L. (2010). Preparing for the first breath: genetic and cellular mechanisms in lung development. *Dev Cell* 18, 8-23.
15. Bellusci, S., Grindley, J., Emoto, H., Itoh, N., and Hogan, B.L. (1997). Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. *Development* 124, 4867-4878.
16. Min, H., Danilenko, D.M., Scully, S.A., Bolon, B., Ring, B.D., Tarpley, J.E., DeRose, M., and Simonet, W.S. (1998). Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. *Genes Dev* 12, 3156-3161.
17. Sekine, K., Ohuchi, H., Fujiwara, M., Yamasaki, M., Yoshizawa, T., Sato, T., Yagishita, N., Matsui, D., Koga, Y., Itoh, N., and Kato, S. (1999). Fgf10 is essential for limb and lung formation. *Nat Genet* 21, 138-141.
18. De Moerloose, L., Spencer-Dene, B., Revest, J.M., Hajihosseini, M., Rosewell, I., and Dickson, C. (2000). An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. *Development* 127, 483-492.
19. Weaver, M., Dunn, N.R., and Hogan, B.L. (2000). Bmp4 and Fgf10 play opposing roles during lung bud morphogenesis. *Development* 127, 2695-2704.
20. Abler, L.L., Mansour, S.L., and Sun, X. (2009). Conditional gene inactivation reveals roles for Fgf10 and Fgfr2 in establishing a normal pattern of epithelial branching in the mouse lung. *Dev Dyn* 238, 1999-2013.
21. Ramasamy, S.K., Mailleux, A.A., Gupte, V.V., Mata, F., Sala, F.G., Veltmaat, J.M., Del Moral, P.M., De Langhe, S., Parsa, S., Kelly, L.K., Kelly, R., Shia, W., Keshet, E., Minoo, P., Warburton, D., and Bellusci, S. (2007). Fgf10 dosage is critical for the amplification of epithelial cell progenitors and for the formation of multiple mesenchymal lineages during lung development. *Dev Biol* 307, 237-247.
22. Warburton, D. (2008). Developmental biology: order in the lung. *Nature* 453, 733-735.
23. Hyatt, B.A., Shanguan, X., and Shannon, J.M. (2004). FGF-10 induces SP-C and Bmp4 and regulates proximal-distal patterning in embryonic tracheal epithelium. *Am J Physiol Lung Cell Mol Physiol* 287, L1116-1126.
24. Ornitz, D.M., and Yin, Y. (2012). Signaling networks regulating development of the lower respiratory tract. *Cold Spring Harb Perspect Biol* 4.
25. Volckaert, T., Campbell, A., Dill, E., Li, C., Minoo, P., and De Langhe, S. (2013). Localized Fgf10 expression is not required for lung branching morphogenesis but prevents differentiation of epithelial progenitors. *Development* 140, 3731-3742.
26. Park, W.Y., Miranda, B., Lebeche, D., Hashimoto, G., and Cardoso, W.V. (1998). FGF-10 is a chemotactic factor for distal epithelial buds during lung development. *Dev Biol* 201, 125-134.

27. Warburton, D., Bellusci, S., De Langhe, S., Del Moral, P.M., Fleury, V., Mailleux, A., Tefft, D., Unbekandt, M., Wang, K., and Shi, W. (2005). Molecular mechanisms of early lung specification and branching morphogenesis. *Pediatr Res* 57, 26R-37R.
28. Li, J., Wang, Z., Chu, Q., Jiang, K., Li, J., and Tang, N. (2018). The Strength of Mechanical Forces Determines the Differentiation of Alveolar Epithelial Cells. *Dev Cell* 44, 297-312 e295.
29. Mailleux, A.A., Kelly, R., Veltmaat, J.M., De Langhe, S.P., Zaffran, S., Thiery, J.P., and Bellusci, S. (2005). Fgf10 expression identifies parabronchial smooth muscle cell progenitors and is required for their entry into the smooth muscle cell lineage. *Development* 132, 2157-2166.
30. Yuan, T., Volckaert, T., Chanda, D., Thannickal, V.J., and De Langhe, S.P. (2018). Fgf10 Signaling in Lung Development, Homeostasis, Disease, and Repair After Injury. *Front Genet* 9, 418.
31. Zhou, Y., Horowitz, J.C., Naba, A., Ambalavanan, N., Atabai, K., Balestrini, J., Bitterman, P.B., Corley, R.A., Ding, B.S., Engler, A.J., Hansen, K.C., Hagood, J.S., Kheradmand, F., Lin, Q.S., Neptune, E., Niklason, L., Ortiz, L.A., Parks, W.C., Tschumperlin, D.J., White, E.S., Chapman, H.A., and Thannickal, V.J. (2018). Extracellular matrix in lung development, homeostasis and disease. *Matrix Biol* 73, 77-104.
32. Mecham, R.P. (2018). Elastin in lung development and disease pathogenesis. *Matrix Biol* 73, 6-20.
33. Nguyen, N.M., Miner, J.H., Pierce, R.A., and Senior, R.M. (2002). Laminin alpha 5 is required for lobar septation and visceral pleural basement membrane formation in the developing mouse lung. *Dev Biol* 246, 231-244.
34. Sakai, T., Larsen, M., and Yamada, K.M. (2003). Fibronectin requirement in branching morphogenesis. *Nature* 423, 876-881.
35. Chen, J., and Krasnow, M.A. (2012). Integrin Beta 1 suppresses multilayering of a simple epithelium. *PLoS One* 7, e52886.
36. Loscertales, M., Nicolaou, F., Jeanne, M., Longoni, M., Gould, D.B., Sun, Y., Maalouf, F.I., Nagy, N., and Donahoe, P.K. (2016). Type IV collagen drives alveolar epithelial-endothelial association and the morphogenetic movements of septation. *BMC Biol* 14, 59.
37. Walma, D.A.C., and Yamada, K.M. (2020). The extracellular matrix in development. *Development* 147.
38. Sato-Nishiuchi, R., Nakano, I., Ozawa, A., Sato, Y., Takeichi, M., Kiyozumi, D., Yamazaki, K., Yasunaga, T., Futaki, S., and Sekiguchi, K. (2012). Polydom/SVEP1 is a ligand for integrin alpha9beta1. *J Biol Chem* 287, 25615-25630.
39. Samuelov, L., Li, Q., Bochner, R., Najor, N.A., Albrecht, L., Malchin, N., Goldsmith, T., Grafi-Cohen, M., Vodo, D., Fainberg, G., Meilik, B., Goldberg, I., Warshauer, E., Rogers, T., Edie, S., Ishida-Yamamoto, A., Burzenski, L., Erez, N., Murray, S.A., Irvine, A.D., Shultz, L., Green, K.J., Uitto, J., Sprecher, E., and Sarig, O. (2017). SVEP1 plays a crucial role in epidermal differentiation. *Exp Dermatol* 26, 423-430.
40. Karpanen, T., Padberg, Y., van de Pavert, S.A., Dierkes, C., Morooka, N., Peterson-Maduro, J., van de Hoek, G., Adrian, M., Mochizuki, N., Sekiguchi, K., Kiefer, F., Schulte, D., and Schulte-Merker, S. (2017). An Evolutionarily Conserved Role for Polydom/Svep1 During Lymphatic Vessel Formation. *Circ Res* 120, 1263-1275.
41. Morooka, N., Futaki, S., Sato-Nishiuchi, R., Nishino, M., Totani, Y., Shimono, C., Nakano, I., Nakajima, H., Mochizuki, N., and Sekiguchi, K. (2017). Polydom Is an Extracellular Matrix Protein Involved in Lymphatic Vessel Remodeling. *Circ Res* 120, 1276-1288.
42. Blake, J.A., Baldarelli, R., Kadin, J.A., Richardson, J.E., Smith, C.L., Bult, C.J., and Mouse Genome Database, G. (2020). Mouse Genome Database (MGD): Knowledgebase for mouse-human comparative biology. *Nucleic Acids Res*.

43. Kishore, R., Arnaboldi, V., Van Slyke, C.E., Chan, J., Nash, R.S., Urbano, J.M., Dolan, M.E., Engel, S.R., Shimoyama, M., Sternberg, P.W., and Genome Resources, T.A.O. (2020). Automated generation of gene summaries at the Alliance of Genome Resources. Database (Oxford) 2020.
44. Dickinson, M.E., Flenniken, A.M., Ji, X., Teboul, L., Wong, M.D., White, J.K., Meehan, T.F., Weninger, W.J., Westerberg, H., Adissu, H., Baker, C.N., Bower, L., Brown, J.M., Caddle, L.B., Chiani, F., Clary, D., Cleak, J., Daly, M.J., Denegre, J.M., Doe, B., Dolan, M.E., Edie, S.M., Fuchs, H., Gailus-Durner, V., Galli, A., Gambadoro, A., Gallegos, J., Guo, S., Horner, N.R., Hsu, C.W., Johnson, S.J., Kalaga, S., Keith, L.C., Lanoue, L., Lawson, T.N., Lek, M., Mark, M., Marschall, S., Mason, J., McElwee, M.L., Newbigging, S., Nutter, L.M., Peterson, K.A., Ramirez-Solis, R., Rowland, D.J., Ryder, E., Samocha, K.E., Seavitt, J.R., Selloum, M., Szoke-Kovacs, Z., Tamura, M., Trainor, A.G., Tudose, I., Wakana, S., Warren, J., Wendling, O., West, D.B., Wong, L., Yoshiki, A., International Mouse Phenotyping, C., Jackson, L., Infrastructure Nationale Phenomin, I.C.d.I.S., Charles River, L., Harwell, M.R.C., Toronto Centre for, P., Wellcome Trust Sanger, I., Center, R.B., MacArthur, D.G., Tocchini-Valentini, G.P., Gao, X., Flicek, P., Bradley, A., Skarnes, W.C., Justice, M.J., Parkinson, H.E., Moore, M., Wells, S., Braun, R.E., Svenson, K.L., de Angelis, M.H., Herault, Y., Mohun, T., Mallon, A.M., Henkelman, R.M., Brown, S.D., Adams, D.J., Lloyd, K.C., McKerlie, C., Beaudet, A.L., Bucan, M., and Murray, S.A. (2016). High-throughput discovery of novel developmental phenotypes. *Nature* 537, 508-514.
45. Skarnes, W.C., Rosen, B., West, A.P., Koutsourakis, M., Bushell, W., Iyer, V., Mujica, A.O., Thomas, M., Harrow, J., Cox, T., Jackson, D., Severin, J., Biggs, P., Fu, J., Nefedov, M., de Jong, P.J., Stewart, A.F., and Bradley, A. (2011). A conditional knockout resource for the genome-wide study of mouse gene function. *Nature* 474, 337-342.
46. Truett, G.E., Heeger, P., Mynatt, R.L., Truett, A.A., Walker, J.A., and Warman, M.L. (2000). Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). *Biotechniques* 29, 52, 54.
47. Ye, J., Coulouris, G., Zaretskaya, I., Cutcutache, I., Rozen, S., and Madden, T.L. (2012). Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. *BMC Bioinformatics* 13, 134.
48. Riddle, R.D., Johnson, R.L., Laufer, E., and Tabin, C. (1993). Sonic hedgehog mediates the polarizing activity of the ZPA. *Cell* 75, 1401-1416.
49. Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 9, 671-675.
50. Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Cech, M., Chilton, J., Clements, D., Coraor, N., Gruning, B.A., Guerler, A., Hillman-Jackson, J., Hiltmann, S., Jalili, V., Rasche, H., Soranzo, N., Goecks, J., Taylor, J., Nekrutenko, A., and Blankenberg, D. (2018). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids Res* 46, W537-W544.
51. Wingett, S.W., and Andrews, S. (2018). FastQ Screen: A tool for multi-genome mapping and quality control. *F1000Res* 7, 1338.
52. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15-21.
53. Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count data. *Genome Biol* 11, R106.
54. Le Meur, N., and Gentleman, R. (2012). Analyzing biological data using R: methods for graphs and networks. *Methods Mol Biol* 804, 343-373.

55. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat Commun* 10, 1523.
56. Richardson, J.E., and Bult, C.J. (2015). Visual annotation display (VLAD): a tool for finding functional themes in lists of genes. *Mamm Genome* 26, 567-573.
57. Sekiguchi, R., and Hauser, B. (2019). Preparation of Cells from Embryonic Organs for Single-Cell RNA Sequencing. *Curr Protoc Cell Biol* 83, e86.
58. Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., 3rd, Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. *Cell* 177, 1888-1902 e1821.
59. Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 36, 411-420.
60. Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nature Biotechnology* 36, 411-420.
61. Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., III, Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. *Cell* 177, 1888-1902.e1821.
62. Chung, N.C., and Storey, J.D. (2015). Statistical significance of variables driving systematic variation in high-dimensional data. *Bioinformatics* 31, 545-554.
63. Macosko, Evan Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, Allison R., Kamitaki, N., Martersteck, Emily M., Trombetta, John J., Weitz, David A., Sanes, Joshua R., Shalek, Alex K., Regev, A., and McCarroll, Steven A. (2015). Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. *Cell* 161, 1202-1214.
64. McInnes, L., and Healy, J. (2018). UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction.
65. Du, Y., Guo, M., Whitsett, J.A., and Xu, Y. (2015). 'LungGENS': a web-based tool for mapping single-cell gene expression in the developing lung. *Thorax* 70, 1092-1094.
66. Zhang, X., Lan, Y., Xu, J., Quan, F., Zhao, E., Deng, C., Luo, T., Xu, L., Liao, G., Yan, M., Ping, Y., Li, F., Shi, A., Bai, J., Zhao, T., Li, X., and Xiao, Y. (2018). CellMarker: a manually curated resource of cell markers in human and mouse. *Nucleic Acids Research* 47, D721-D728.
67. Haghverdi, L., Lun, A.T.L., Morgan, M.D., and Marioni, J.C. (2018). Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. *Nature Biotechnology* 36, 421-427.
68. Beauchemin, K.J., Wells, J.M., Kho, A.T., Philip, V.M., Kamir, D., Kohane, I.S., Graber, J.H., and Bult, C.J. (2016). Temporal dynamics of the developing lung transcriptome in three common inbred strains of laboratory mice reveals multiple stages of postnatal alveolar development. *PeerJ* 4, e2318.
69. Desai, T.J., Brownfield, D.G., and Krasnow, M.A. (2014). Alveolar progenitor and stem cells in lung development, renewal and cancer. *Nature* 507, 190-194.
70. Yvernogeau, L., Klaus, A., Maas, J., Morin-Poulard, I., Weijts, B., Schulte-Merker, S., Berezikov, E., Junker, J.P., and Robin, C. (2020). Multispecies RNA tomography reveals regulators of hematopoietic stem cell birth in the embryonic aorta. *Blood* 136, 831-844.
71. McGowan, S.E., Grossmann, R.E., Kimani, P.W., and Holmes, A.J. (2008). Platelet-derived growth factor receptor-alpha-expressing cells localize to the alveolar entry ring and have characteristics of myofibroblasts during pulmonary alveolar septal formation. *Anat Rec (Hoboken)* 291, 1649-1661.

72. Branchfield, K., Li, R., Lungova, V., Verheyden, J.M., McCulley, D., and Sun, X. (2016). A three-dimensional study of alveologenesis in mouse lung. *Dev Biol* 409, 429-441.
73. Gouveia, L., Betsholtz, C., and Andrae, J. (2018). PDGF-A signaling is required for secondary alveolar septation and controls epithelial proliferation in the developing lung. *Development* 145.
74. Betsholtz, C. (2004). Insight into the physiological functions of PDGF through genetic studies in mice. *Cytokine Growth Factor Rev* 15, 215-228.
75. Ntokou, A., Klein, F., Dontireddy, D., Becker, S., Bellusci, S., Richardson, W.D., Szibor, M., Braun, T., Morty, R.E., Seeger, W., Voswinckel, R., and Ahlbrecht, K. (2015). Characterization of the platelet-derived growth factor receptor- α -positive cell lineage during murine late lung development. *Am J Physiol Lung Cell Mol Physiol* 309, L942-958.
76. Li, R., Bernau, K., Sandbo, N., Gu, J., Preissl, S., and Sun, X. (2018). *Pdgfra* marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury response. *Elife* 7.
77. Naizhen, X., Kido, T., Yokoyama, S., Linnoila, R.I., and Kimura, S. (2019). Spatiotemporal Expression of Three Secretoglobin Proteins, SCGB1A1, SCGB3A1, and SCGB3A2, in Mouse Airway Epithelia. *J Histochem Cytochem* 67, 453-463.
78. Dixit, R., Ai, X., and Fine, A. (2013). Derivation of lung mesenchymal lineages from the fetal mesothelium requires hedgehog signaling for mesothelial cell entry. *Development* 140, 4398-4406.
79. Moiseenko, A., Kheirollahi, V., Chao, C.M., Ahmadvand, N., Quantius, J., Wilhelm, J., Herold, S., Ahlbrecht, K., Morty, R.E., Rizvanov, A.A., Minoo, P., El Agha, E., and Bellusci, S. (2017). Origin and characterization of α smooth muscle actin-positive cells during murine lung development. *Stem Cells* 35, 1566-1578.
80. del Moral, P.M., De Langhe, S.P., Sala, F.G., Veltmaat, J.M., Tefft, D., Wang, K., Warburton, D., and Bellusci, S. (2006). Differential role of FGF9 on epithelium and mesenchyme in mouse embryonic lung. *Dev Biol* 293, 77-89.
81. Yi, L., Domyan, E.T., Lewandoski, M., and Sun, X. (2009). Fibroblast growth factor 9 signaling inhibits airway smooth muscle differentiation in mouse lung. *Dev Dyn* 238, 123-137.
82. Goodwin, K., Mao, S., Guyomar, T., Miller, E., Radisky, D.C., Kosmrlj, A., and Nelson, C.M. (2019). Smooth muscle differentiation shapes domain branches during mouse lung development. *Development* 146.
83. Danopoulos, S., Shiosaki, J., and Al Alam, D. (2019). FGF Signaling in Lung Development and Disease: Human Versus Mouse. *Front Genet* 10, 170.
84. Shefer, G., and Benayahu, D. (2010). SVEP1 is a novel marker of activated pre-determined skeletal muscle satellite cells. *Stem Cell Rev Rep* 6, 42-49.
85. Streuli, C. (1999). Extracellular matrix remodelling and cellular differentiation. *Curr Opin Cell Biol* 11, 634-640.

Figure 1

Figure 2

Figure 1. Lungs of *Svep1*^{-/-} mice are hypoplastic and lobulated. (A) *In situ* hybridization of E14.5 wild type mice lungs showed strong *Svep1* mRNA expression in the mesenchyme at the lung periphery and around bifurcating distal airways tips (right inset outlined in red, arrowhead). **(B-D)** SVEP1 protein immunofluorescence in the lung mesenchyme of *Svep1*^{+/+} embryos. **(B)** White arrows indicate the location of the SVEP1 (green) protein between the epithelial membrane stained with ECAD (purple) in the most distal airway buds of the lungs of *Svep1*^{+/+} E12.5 embryos. **(C)** The mesenchyme of E14.5 lung tips expresses a high level of SVEP1. The white arrowhead shows branching cleft sites, while the white arrow indicates the growing vasculature. **(D)** SVEP1 protein in E18.5 lungs is located in the lung parenchyma including the primary septa and adjacent to the proximal epithelium. **(E)** microCT scan of E18.5 embryos of showing lung hypoplasia (red arrows) and potential thin diaphragm in *Svep1*^{-/-} mice relative to normal controls. **(F)** Ventral view of E18.5 of *Svep1*^{+/+} and *Svep1*^{-/-} lungs. Lung lobes in *Svep1*^{-/-} mice are rounded and fail to cover the heart (black arrowheads). The right caudal lobe (RCa) of *Svep1*^{-/-} embryos has a lobulated appearance that resembles cauliflower (inset). **(G)** H&E stained lung sections from E16.5 embryos demonstrating that, compared to wild type embryos, lungs from *Svep1*^{-/-} embryos are smaller and have irregular lobe edges (black arrowheads). Co-localization of epithelial marker (ECAD) and epithelial progenitor maker (SOX9) showing distal airways that are densely packed in *Svep1*^{-/-} lungs at E16.5 (white arrows). Distal tips of lungs from mutant embryos are rounded and exhibit an increased density of distal airways (white arrowheads). **(H)** H&E stained sections of E18.5 lungs showing the dorsal (red arrowheads) and ventral side (black arrows) of E18.5 lungs. *Svep1*^{-/-} lungs show defects in sacculization, particularly in the lobulated ventral side of the lung (black arrows), and hypercellular mesothelium (arrowhead in inserts). Co-localization of ECAD and SOX9 showing high expression of SOX9 in the lung edge distal airways of *Svep1*^{-/-} embryos at E18.5 (white arrowheads), Right cranial (RCr), Right Caudal (RCa), Right Medial (RMe), and Right Accessory (RAc) lobes. Scale bars: 50mm (**A, B, C, D**), 100 mm (**G, H**).

Figure 2

Figure 2. Loss of *Svep1* leads to an aberrant increased in distal airways resulting in lobe shape defects. *Right cranial (RCr), Right Caudal (RCa), Right Medial (RMe), and Right Accessory (RAc) lobes.* Scale bars: 100mm **(A-D)** Representative Z-stack images showing SOX9 immunofluorescence of whole lung or individual lobes in *Svep1*^{+/+} and *Svep1*^{-/-} mice at E13.5 and E14.5. **(A)** Whole lungs at E13.5 illustrating the abnormal shape of the RCa lobe in the lung of mutant lung embryos (white arrowhead). Main bronchi of lungs from *Svep1*^{+/+} embryos end a solo distal tip (lower left inset; white arrow) and two distal tips in *Svep1*^{-/-} embryos (right lower inset; white arrow). Lung budding defects are also observed in mutant embryos (right lower inset; white arrowheads). **(B)** Left lung lobes of *Svep1*^{+/+} and *Svep1*^{-/-} embryos at E13.5 illustrating branching/budding defects in mutant embryos. The areas outlined in pink in the bottom insets show the main airways. E13.5 Abnormal branching/budding in the distal lobe of *Svep1*^{-/-} embryos marked by arrows (orange arrow points to a mis localized airway bud). **(C)** E14.5 left lung lobes of *Svep1*^{+/+} and *Svep1*^{-/-} embryos. SOX9⁺ buds highlighted in pink show abnormal airway tip arrangement (white arrows) in mutants resulting in abnormal tip lung tip morphology in *Svep1*^{-/-} embryos. **(D)** Immunofluorescence of SOX9 of the left lung lobe at E14.5 shows airway disorganization in *Svep1*^{-/-} compared to *Svep1*^{+/+} embryos. Distal lung tips indicated by arrowheads. Branching trifurcation in the *Svep1*^{-/-} embryo is shown (white arrow). **(E)** Lungs of *Svep1*^{-/-} embryos at E14.5 have a statistically significant increase in number of SOX9 positive airway tips compared to wild type embryos.

Figure 3

Figure 3. *Svep1*^{-/-} lung airways undergo ectopic branching and increased trifurcation. (A)

Compilation of a Z-stack image series for tissue-cleared whole RAc lung lobes labeled with ECAD (green) and SOX9 (red) showing disorganized branching in *Svep1*^{-/-} embryos at E14.5 (highlight). Arrows point to branching airways with rosette-like arrangement and airway tips growing in different directions. Arrowheads indicate the RCa lobe tips showing a single tip in the lobe of *Svep1*^{+/+} embryos and multi branched tips in *Svep1* knockout embryos. **(B)** Schematic illustrating representative domain (blue), planar (green), and orthogonal (red) branching programs of *Svep1*^{+/+} and *Svep1*^{-/-} RAc lobes. Lungs of *Svep1*^{-/-} embryos lack planar bifurcations and have many trifurcating branch tips (red highlighted in black). **(C)** Single Z-stack image of RAc lobes at E14.5 stained with ECAD (green) and SOX9 (red) showing bifurcations (white dotted lines and a white arrowhead) in *Svep1*^{+/+} embryos and trifurcations (white dotted lines and white arrows) in *Svep1*^{-/-} mice. **(D)** Single Z-stack image of RAc lobes stained with ECAD (green) and SOX9 (red) displaying ectopic branching in first domain in *Svep1*^{-/-} mice. **(E)** Lung explants from E12.5 embryos after 48 hours in organ culture. Explants from *Svep1*^{+/+} embryos show normal bifurcation (black arrowheads) whereas explants from *Svep1*^{-/-} embryos show obvious trifurcations (black arrows) and ectopic budding (red arrowheads). Scale bars 100μm (A, E); 50μm (C)

Figure 4

Figure 4. *Svep1* mutants have deficiencies in alveolar differentiation. (A) Paraffin-embedded semi-thin section of E18.5 lungs stained with toluidine blue. Type I pneumocytes (AT1) are outlined by black dotted lines; Type II pneumocytes (AT2) are outlined with red dotted lines. Round AT2 clusters tightly in immature saccules in *Svep1*^{-/-} lungs. Black arrowheads indicate secreted surfactant protein; black arrows indicate capillaries. (B) Expression heatmaps of selected genes associated with type I (AT1) and type II pneumocytes (AT2). *Svep1*^{-/-} lungs have lower expression of type 1 genes compared to *Svep1*^{+/+} lungs and higher expression of type 2 associated genes. (C) Immunofluorescence of Podoplanin (arrows) in the lungs of E18.5 embryos. (D) Localization of Pro-SFTPC in E18.5 lungs. Arrowheads indicate Pro-SFTPC in the lung edges distal epithelium. Scale bars 25 μ m (F); 50 μ m (G)

Figure 5

Figure 5. *Svep1*^{-/-} embryos have impaired smooth differentiation in the distal lung. (A) Gene expression heatmap from bulk RNA Seq data showing the top downregulated genes in lungs from *Svep1*^{-/-} embryos associated with smooth muscle cells. **(B)** ACTA2 localization marking smooth muscle cells at E18.5. White arrows indicate respiratory bronchioles; orange arrows indicate proximal bronchioles; white arrowheads indicate blood vessels **(C)** ACTA2 staining (red) in wild type and *Svep1*^{-/-} E12.5 lung explants that were cultured for six days show a dramatic reduction of smooth muscle cell formation in secondary and tertiary bronchi (white arrow). **(D)** Alveolar localization of PDGFRA (green) labeled progenitors and ACTA2 (red) labeled mature myofibroblast (arrows). **(E-F)** Plots show PDGFRA total count (E) and the ratio of ACTA2+ cells that are also PDGFRA+ (F). Data shown are average counts $\pm$ SD; $p < 0.05$.

Figure 6

Figure 6. Loss of *Svep1* leads to proximal conductive airway hypoplasia and defects in microvasculature formation and mesothelium differentiation. **(A)** Immunofluorescence of SCGB1A1 (green) club cell marker highlights the lung proximal airways which are reduced in mutants. SCGB1A1 co-localization with the ciliated cell marker FOXJ1 (purple) reveals a multicellular epithelium constituted primarily of club cells. In *Svep1*^{-/-} embryos, the lumen of bronchioles is narrowed. **(B)** Plots showing quantification of SCGB1A1+ and FOXJ1+ cells and ratios in *Svep1*^{-/-} and *Svep1*^{+/+} embryos. **(C)** Co-labeling of endothelial cell nucleus with ERG (red) and type I pneumocytes (AT1) with Podoplanin (PDPL; green) at E18.5. **(D)** Immunofluorescence for the mesothelial progenitor marker WT1 (red) showing that *Svep1*^{-/-} lungs have a greater number of WT1 progenitors. **(E)** Plots exhibit the total number of WT1 at E18.5 and percentage of WT1+ and KI67+ at E16.5 and A18.5. **(F)** Immunofluorescence for WT1 (purple) and KI67 (green). Arrows indicate regions of WT1+ cell proliferation. *Scale bars* 200 μ m (D); 100 μ m (B,D,E,G).

Figure 7

Figure 7. SVEP1 acts as a negative regulator of branching and the FGF pathway mediates smooth muscle differentiation defects in *Svep1*^{-/-} lungs. (A) Lung explants from E12.5 *Svep1*^{+/-} embryos cultured for 48 hours with and without SVEP1 peptide. Treated lung explants show a reduction of branching. **(B)** Plot of peripheral airways counts in lung explants from *Svep1*^{+/-} and *Svep1*^{-/-} E12.5 embryos following SVEP1 peptide treatment. *Svep1*^{-/-} lung explants show a significant reduction of peripheral airways. **(C)** E12.5 lung explants treated with SVEP1 peptide ex vivo for 48 hours. Black arrowheads indicate normal bifurcation in *Svep1*^{+/-} and *Svep1*^{-/-} lungs. Arrows indicate rare trifurcations in *Svep1*^{-/-} lung explants treated with rSVEP1. **(D)** *In situ* hybridization of *Fgfr2* demonstrates increased expression in *Svep1*^{-/-} mutants. **(E)** Plot of relative transcript abundance of *Fgfr2* (and its isoforms *Fgf2b* and *Fgf2c*), *Fgf10*, *Fgf9*, and *Kras*. **(F)** *Ex vivo* *Svep1*^{+/-} and *Svep1*^{-/-} lungs from E12.5 treated with the FGF signaling inhibitor SU5402. The regions outlined with dotted lines are shown in higher magnification and demonstrate the distal tip trifurcations in lung explants from *Svep1*^{-/-} embryos. SOX9 (green) and ACTA2 (purple) staining confirm branching anomalies (highlighted in the white dotted areas) in *Svep1*^{-/-} lung explants. Arrowheads point to trifurcations; arrows indicate abnormal branching; the red arrowhead highlights ectopic budding. **(G)** E12.5 lung explants treated with SU5402 (2.5 µg/ml) for 4 days stained with ACTA2 (green). Inserts showing ACTA2 localization in distal airways of normal and mutant lungs.